Abstract Among different FAPIs (fibroblast activation protein inhibitors) developed for PET imaging, 68 Ga-FAPI-04 has demonstrated the most impressive properties with low nanomolar affinity to FAP, near-complete internalization of radioactivity bound and rapid blood clearance. The application been extended 28 kinds clinical cancer detection. manual synthesis is like other Ga-labeling peptides,...

PURPOSE The present study aims at developing and evaluating an urea-based prostate specific membrane antigen (PSMA) inhibitor suitable for labeling with 111In for SPECT and intraoperative applications as well as 68Ga and 64Cu for PET imaging. METHODS The PSMA-based inhibitor-lysine-urea-glutamate-coupled to the spacer Phe-Phe-D-Lys(suberoyl) and functionalized with the enantiomerically pure p...

Improvement of the accuracy of dosimetry in radionuclide therapy has the potential to increase patient safety and therapeutic outcomes. Although positron emission tomography (PET) is ideally suited for acquisition of dosimetric data because PET is inherently quantitative and offers high sensitivity and spatial resolution, it is not directly applicable for this purpose because common therapeutic...

Aim: PSMA expression has been observed in increased levels patients with high Gleason scores. Current information on Ga-68 PET/CT shows that primary staging is important high-risk PC. may also have a place intermediate risk PC, but only few data are available at present. In this study, we aimed to elucidate the relationship between value prostate gland, total PSA and GS diagnosed cancer.
 ...

Prostate cancer-specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-...